X-153693083-G-A
Variant summary
Our verdict is Uncertain significance. Variant got -4 ACMG points: 0P and 4B. BS2
This summary comes from the ClinGen Evidence Repository: The NM_005629.4:c.820G>A variant in SLC6A8 is a missense variant predicted to cause the substitution of a valine by a methionine at amino acid position 274 (p.Val274Met). This variant has been previously reported in one individual with hypotonia, global developmental delay, and microcephaly, but who was found to have normal urine creatine and guanidinoacetate levels on two separate occasions and a de novo variant in KAT6A as an alternate molecular cause of his symptoms (PMID 27133397) (BS2). In gnomAD v2.1.1, the highest population allele frequency is 0.00015 (14/91767 alleles) in the European (Non-Finnish) population and there are 4 hemizygotes across all populations, which is greater than the ClinGen CCDS VCEP’s threshold for PM2_Supporting (<0.00002) but less than the ClinGen CCDS VCEP’s threshold for BS1 (>0.0002), such that neither of these criteria are met. The computational predictor REVEL gives a score of 0.559, which is less than the ClinGen CCDS VCEP’s threshold for PP3 (>0.75) but greater than the ClinGen CCDS VCEP’s threshold for BP4 (<0.2), such that neither of these criteria are met. There is a ClinVar entry for this variant (Variation ID: 4416002). In summary, this variant meets the criteria to be classified as a variant of uncertain significance for creatine transporter deficiency. SLC6A8-specific ACMG-AMP criteria applied, as specified by the ClinGen CCDS VCEP (Specifications Version 1.1.0): BS2.(Classification approved by the ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel on November 8, 2024) LINK:https://erepo.genome.network/evrepo/ui/classification/CA10549333/MONDO:0010305/027
Frequency
Consequence
NM_005629.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got -4 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SLC6A8 | NM_005629.4 | c.820G>A | p.Val274Met | missense_variant | 5/13 | ENST00000253122.10 | NP_005620.1 | |
SLC6A8 | NM_001142805.2 | c.820G>A | p.Val274Met | missense_variant | 5/13 | NP_001136277.1 | ||
SLC6A8 | NM_001142806.1 | c.475G>A | p.Val159Met | missense_variant | 5/13 | NP_001136278.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SLC6A8 | ENST00000253122.10 | c.820G>A | p.Val274Met | missense_variant | 5/13 | 1 | NM_005629.4 | ENSP00000253122.5 |
Frequencies
GnomAD3 genomes AF: 0.0000532 AC: 6AN: 112691Hom.: 0 Cov.: 24 AF XY: 0.0000861 AC XY: 3AN XY: 34851
GnomAD3 exomes AF: 0.0000714 AC: 13AN: 182136Hom.: 0 AF XY: 0.0000446 AC XY: 3AN XY: 67194
GnomAD4 exome AF: 0.0000976 AC: 107AN: 1096467Hom.: 0 Cov.: 32 AF XY: 0.0000911 AC XY: 33AN XY: 362203
GnomAD4 genome AF: 0.0000532 AC: 6AN: 112691Hom.: 0 Cov.: 24 AF XY: 0.0000861 AC XY: 3AN XY: 34851
ClinVar
Submissions by phenotype
not provided Uncertain:2Benign:1
Uncertain significance, no assertion criteria provided | clinical testing | Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center | - | - - |
Likely benign, criteria provided, single submitter | clinical testing | GeneDx | Jul 27, 2018 | - - |
Uncertain significance, no assertion criteria provided | clinical testing | Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen | - | - - |
Creatine transporter deficiency Uncertain:1Benign:1
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 09, 2024 | - - |
Uncertain significance, reviewed by expert panel | curation | ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel, ClinGen | Nov 08, 2024 | The NM_005629.4:c.820G>A variant in SLC6A8 is a missense variant predicted to cause the substitution of a valine by a methionine at amino acid position 274 (p.Val274Met). This variant has been previously reported in one individual with hypotonia, global developmental delay, and microcephaly, but who was found to have normal urine creatine and guanidinoacetate levels on two separate occasions and a de novo variant in KAT6A as an alternate molecular cause of his symptoms (PMID 27133397) (BS2). In gnomAD v2.1.1, the highest population allele frequency is 0.00015 (14/91767 alleles) in the European (Non-Finnish) population and there are 4 hemizygotes across all populations, which is greater than the ClinGen CCDS VCEP’s threshold for PM2_Supporting (<0.00002) but less than the ClinGen CCDS VCEP’s threshold for BS1 (>0.0002), such that neither of these criteria are met. The computational predictor REVEL gives a score of 0.559, which is less than the ClinGen CCDS VCEP’s threshold for PP3 (>0.75) but greater than the ClinGen CCDS VCEP’s threshold for BP4 (<0.2), such that neither of these criteria are met. There is a ClinVar entry for this variant (Variation ID: 4416002). In summary, this variant meets the criteria to be classified as a variant of uncertain significance for creatine transporter deficiency. SLC6A8-specific ACMG-AMP criteria applied, as specified by the ClinGen CCDS VCEP (Specifications Version 1.1.0): BS2. (Classification approved by the ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel on November 8, 2024) - |
SLC6A8-related disorder Benign:1
Likely benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Apr 21, 2022 | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at